Navigation Links
New Drug Regimens May Slow Advanced Breast Cancer

By Amy Norton
HealthDay Reporter

WEDNESDAY, Dec. 5 (HealthDay News) -- An experimental cancer drug may delay the progression of some advanced breast cancers, while a double dose of an existing cancer drug could help women live longer, according to separate studies reported Wednesday.

In one study, of nearly 200 women, researchers tested the effects of adding the experimental drug -- known for now as PD 0332991 -- to Femara (letrozole), a hormonal therapy already used to treat certain breast cancers.

They found that women on the combination had a much longer "progression-free survival" -- the time a cancer patient lives with the disease without it getting worse. For women on the combination therapy, that period was typically 26 months, versus less than eight months among women given Femara alone.

"That's a dramatic difference," said lead researcher Dr. Richard Finn, associate professor of medicine at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center.

Finn noted that in oncology clinical trials, success is measured in very small steps. A new drug might extend patients' lives by a matter of a couple of months, for instance.

The women in the trial all had advanced cancer that had spread beyond the breast. Their tumors were also estrogen-receptor positive, which means the cancer depends on estrogen to feed its growth and spread.

"ER-positive breast cancer is the most common form of breast cancer," Finn said. "And while we do have effective therapies for it, we still need to improve upon them."

The experimental drug is made by Pfizer, Inc., which also funded the trial. A larger trial is set to start next year, but Finn said these early results are "encouraging."

He was scheduled to present the findings Wednesday at the 2012 San Antonio Breast Cancer Symposium in Texas. Data and conclusions of studies released at medical meetings are considered preliminary, since they haven't undergone peer review for publication in a medical journal.

In a separate study reported at the meeting, researchers found that doubling the dose of an existing breast cancer drug, Faslodex (fulvestrant), lengthened women's lives by a few months.

Like the other trial, this one focused on older women with advanced ER-positive cancer. Faslodex is an injected form of hormonal therapy that works by blocking the effects of estrogen on breast cancer cells; it's given to postmenopausal women whose cancer has worsened despite anti-estrogen therapies such as tamoxifen.

Among more than 700 women in the trial, those randomly assigned to a 500-milligram dose of Faslodex typically lived about four months longer: 26 months versus 22 months among women given the standard 250-milligram dose.

The higher dose extended lives without increasing side effects, said the researchers, led by Dr. Angelo Di Leo, head of medical oncology at the Hospital of Prato in Italy.

Faslodex commonly causes side effects such as nausea, vomiting, diarrhea, headaches and hot flashes, and occasionally more serious problems, such as blood clots. In this trial, between 1 percent and 2 percent of women in each group had a serious side effect attributable to the medication.

The trial was sponsored by AstraZeneca Pharmaceuticals, which makes Faslodex.

The higher Faslodex dose has already become the "standard of care," based on earlier findings from the trial, said Dr. Kimberly Blackwell, director of the Duke Breast Cancer Clinic and a professor of medicine at Duke University School of Medicine.

Blackwell, who was not involved in either new study, was more excited about the experimental Pfizer drug.

"We always want to be cautious about a trial that involves fewer than 200 patients," Blackwell said. But, she added, "if this is confirmed in the Phase 3 trial, it could have a big impact on how we treat patients."

What is new about the drug, Finn and Blackwell said, is how it works: It blocks the formation of certain proteins cancer cells need to divide and spread.

Blackwell said the importance of those proteins has long been recognized, but until now, there hasn't been a drug that could safely block them.

"This represents a brand-new way in slowing down breast cancer progression," Blackwell said.

The combination did cause side effects, including fatigue and neutropenia -- a decrease in important disease-fighting white blood cells. But these "were manageable side effects," Finn said.

Still, Blackwell said, the safety and ultimate effectiveness of the therapy "remain to be validated."

According to the American Cancer Society, the average U.S. woman has a 12 percent chance of developing breast cancer in her lifetime. Death rates from the disease have dropped in recent decades because of better treatments and earlier detection, experts said.

More information

Learn more about breast cancer from the American Cancer Society.

SOURCES: Richard Finn, M.D., associate professor, medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center; Kimberly Blackwell, M.D., director, Duke Breast Cancer Clinic, and professor, medicine, Duke University School of Medicine, Durham, N.C.; Dec. 5, 2012, presentation, San Antonio Breast Cancer Symposium, San Antonio, Texas

Copyright©2012 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. NIH to test maraviroc-based drug regimens for HIV prevention
2. Experimental Gel May Help Those With Advanced Parkinsons
3. Advanced genetic screening method may speed vaccine development
4. Advanced Prostate Cancer Drug May Help at Earlier Stage
5. Obese More Likely to Be Diagnosed With Advanced Thyroid Cancer
6. GW researchers discover biomarker for advanced bile duct fibrosis and bile duct cancer
7. San Francisco’s Advanced Male Medical Center Announces Discount, Discusses Erectile Dysfunction
8. Advanced Osteoarthritis Of The Knee Is Now Being Treated With Regenerative Medicine At The Center For Regenerative Medicine
9. Ecig Advanced Sponsors Lexington's First Annual Vaping Event
10. Lack of insurance linked to advanced stage cervical cancer
11. Clinical trial seeks to cure advanced Crohns disease using bone marrow transplant
Post Your Comments:
(Date:11/30/2015)... ... , ... The Foundation for Breast and Prostate Health (FBPH)—a ... with the award-winning creator and writer of Downton Abbey Julian Fellowes to host ... Union League of Philadelphia. , The benefit, titled “An Evening with Julian ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... Specialty Ingredients (ASI) as their exclusive channel partner for the Nutraceutical Specialties products ... markets in the US, effective immediately. , “We are pleased to announce ...
(Date:11/30/2015)... ... November 30, 2015 , ... California-based i2i Systems, a ... today that Michigan-based Family Health Center (FHC) has selected i2iTracks as their population ... was awarded the largest Affordable Care Act grant for Federally Qualified Health Centers ...
(Date:11/30/2015)... PITTSBURGH, PA (PRWEB) , ... November 30, 2015 , ... ... quality of life in the womb. "My last baby had high blood pressure due ... way for mothers to protect their babies from noise pollution as well as radio ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an interview with Andy ... a top ophthalmologist on Long Island’s east end. During the broadcast, entitled “Eyes: the ... and treatment of glaucoma and cataracts, and how a visit with his grandmother to ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... KIRKLAND, Wash. , Nov. 30, 2015 /PRNewswire/ ... of Post-Processing services, is pleased to announce a ... of medical imaging services. Building on its ISO-9001:2008 ... adopted and implemented comprehensive Core Lab protocols and ... wide variety of research activities.  Their Core Lab ...
(Date:11/30/2015)... 30, 2015 Mexico Healthcare and Life Sciences ... Report 2015 . --> Pharmaboardroom releases its new 98-page ... Latin America , a country of over 122 million ... of over 122 million people. --> It offers companies, ... life sciences insights into the second largest pharma and healthcare market ...
(Date:11/30/2015)... , November 30, 2015 Elbit ... the "Company") announced today that it was informed by InSightec ... Drug Safety (MFDS) has approved its Exablate Neuro system ... --> --> Insightec,s Exablate Neuro ... alternative that combines two technologies: Focused Ultrasound, which is ...
Breaking Medicine Technology: